Infantile hemangioma or hamangioma of infancy is the most common tumor in children, with great variability of presentation. Most cases resolve spontaneously and treatment is usually indicated for specific cases where injury has a high rate of morbidity or disfigurement after regression. The treatment is based on the use of systemic corticosteroids, which can also be used topically or by intralesional injections. Propranolol has been used recently as a new therapeutic option for the treatment of hemangiomas, with satisfactory, permanent results and fewer adverse effects than corticosteroids. This is a report of the case where a child presenting extensive periorbital and frontoparietal hemangioma was treated with propranolol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0365-05962011000400022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re-encountering the phobic cue within days after a reconsolidation intervention is crucial to observe a lasting fear reduction in spider phobia.
Mol Psychiatry
January 2025
Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
Memory reconsolidation interventions offer an exciting alternative to exposure treatment because they may target fear memories directly, thereby preventing relapse. A previous reconsolidation intervention for spider fear abruptly reduced avoidance behaviour, whereas changes in self-reported fear followed later. In this pre-registered placebo-controlled study, we first aimed to conceptually replicate these effects in spider phobia.
View Article and Find Full Text PDFChoroidal Hemangioma Treatment with Propranolol - A Case Study in Sturge-Weber Syndrome and Systematic Literature Review.
Semin Ophthalmol
January 2025
Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, WI, USA.
Purpose: To examine propranolol efficacy in treating diffuse (DCH) and circumscribed choroidal hemangiomas (CCH) and controlling intraocular pressure (IOP) in patients with Sturge-Weber syndrome (SWS).
Methods: A SWS patient case treated with propranolol for DCH is presented. Following PRISMA guidelines, we also performed a systematic review using PubMed/Web of Science, analyzing 14 studies detailing propranolol treatment outcomes for DCH, CCH, and IOP control in SWS.
Neurodevelopmental Effects of Propranolol Treatment During Infancy in Infantile Hemangioma Patients.
Children (Basel)
December 2024
Department of Pediatric Hematology and Oncology, Istanbul Medical Faculty, İstanbul University, 34098 Istanbul, Turkey.
Introduction And Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test.
Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023.
Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China.
Sci Rep
January 2025
Department of Plastic Surgery, Jiangxi Provincial Children's Hospital, 1666 Diezihu Avenue, Nanchang, China.
The objective of this study was to evaluate the efficacy and safety of propranolol hydrochloride tablets and oral solution in neonates with severe IHs. A retrospective cohort study included 184 consecutive neonates diagnosed with severe IHs and treated with propranolol from January 2016 to June 2023. Of these, 126 patients received propranolol tablets, and 58 received propranolol oral solution.
View Article and Find Full Text PDFMulticentre prospective, randomised open-label, endpoint-blinded study to evaluate the safety and efficacy of propranolol for the prevention of stroke-associated pneumonia in patients with intracerebral haemorrhage (PROCHASE): rationale and design.
Stroke Vasc Neurol
December 2024
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Background: Stroke-induced transient immune suppression is believed to contribute to post-stroke infections. The β-adrenergic receptor antagonist, propranolol, has been shown to prevent stroke-associated pneumonia (SAP) via reversing post-stroke immunosuppression in preclinical studies and in retrospective analysis in stroke patients. However, whether propranolol can reduce the risk of SAP has not been tested in prospective, randomised controlled trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!